We found that HR+ was associated with increased prevalence of EGFR mutations in NSCLC patients age≥65 and in males overall, which is interesting as patients with EGFR mutant lung cancer typically have a lower median age than the average age of U.S. lung cancer patients and seen more in females (26). The gene discussed is EGFR; the disease is lung carcinoma.